newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Chemomab Therapeutics Ltd. (NASDAQ: CMMB) will host CEO Dr. Adi Mor & senior management for a corporate presentation & one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference.
  • The conference is scheduled for February 26, 2026, at 8:00 am ET & will be webcast live.
  • The webcast will be archived on the Chemomab investor relations website for 90 days.
  • Chemomab is developing nebokitug, a first-in-class dual activity monoclonal antibody targeting CCL24 to treat fibro-inflammatory diseases.
  • Nebokitug has demonstrated favorable safety & disease-modifying potential across five clinical trials.
  • The FDA has aligned with Chemomab on the design of a Phase 3 registration trial for nebokitug in primary sclerosing cholangitis (PSC) following positive Phase 2 SPRING trial data.
  • Nebokitug holds FDA & EMA Orphan Drug designations, plus an FDA Fast Track designation for PSC treatment.
  • The nebokitug program for systemic sclerosis has received FDA & EMA Orphan Drug designations & maintains an open U.S. IND.